Combination of a COX-2 inhibitor with radiotherapy or radiochemotherapy in the treatment of thoracic cancer

American Journal of Clinical Oncology: Cancer Clinical Trials

Volumn 26, Issue 4 SUPPL. 2, 2003, Pages

  Liao, Zhongxing ^a   Milas, Luka ^a   Komaki, Ritsuko ^b   Stevens, Craig ^a   Cox, James D ^a  

^a UNIVERSITY OF TEXAS MD ANDERSON CANCER CENTER   (United States)

^b NONE

Author keywords

Celecoxib; COX 2; Esophageal cancer; Lung cancer; Radiochemotherapy; Radiotherapy

Indexed keywords

4 [5 (4 CHLOROPHENYL) 3 TRIFLUOROMETHYL 1H PYRAZOL 1 YL]BENZENESULFONAMIDE; CELECOXIB; CISPLATIN; CYCLOOXYGENASE 2; CYCLOOXYGENASE 2 INHIBITOR; FLUOROURACIL; IBUPROFEN; INDOMETACIN;

ANTINEOPLASTIC ACTIVITY; CANCER CHEMOTHERAPY; CANCER RADIOTHERAPY; CLINICAL ARTICLE; CLINICAL TRIAL; CONFERENCE PAPER; DISEASE ASSOCIATION; DYSPNEA; ENZYME INHIBITION; ERYTHEMA; ESOPHAGITIS; ESOPHAGUS CARCINOMA; HUMAN; LUNG CARCINOMA; LUNG NON SMALL CELL CANCER; PHASE 1 CLINICAL TRIAL; RADIATION DOSE; THORAX CANCER;

ANTI-INFLAMMATORY AGENTS, NON-STEROIDAL; ANTINEOPLASTIC AGENTS; CARCINOMA, NON-SMALL-CELL LUNG; CLINICAL TRIALS; CYCLOOXYGENASE 2; CYCLOOXYGENASE 2 INHIBITORS; CYCLOOXYGENASE INHIBITORS; ESOPHAGEAL NEOPLASMS; HUMANS; ISOENZYMES; LUNG NEOPLASMS; MEMBRANE PROTEINS; PROSTAGLANDIN-ENDOPEROXIDE SYNTHASES; PYRAZOLES; RADIATION-SENSITIZING AGENTS; SULFONAMIDES;

EID: 0041573042     PISSN: 02773732     EISSN: None     Source Type: Journal    
DOI: 10.1097/00000421-200308002-00010     Document Type: Conference Paper

References (51)

1. Greenlee R, et al. Cancer statistics. CA Cancer J Clin 2000;50: 7-33.
2. Mountain C. A new international staging system for lung cancer. Chest 1986;89(suppl):225-33.
3. Komaki R, Cox JD, Hartz AJ, et al. Characteristics of long-term survivors after treatment for inoperable carcinoma of the lung. Am J Clin Oncol 1985;8:362-70.
4. Perez C, Stanley K, Grundy G, et al. Impact of irradiation technique and tumor extent in tumor control and survival of patients with unresectable non-oat cell carcinoma of the lung. Cancer 1982;50:1091-9.
5. Dillman RO, Seagren SL, Propert KJ, et al. A randomized trial of induction chemotherapy plus high-dose radiation versus radiation alone in stage III non-small-cell lung cancer. N Engl J Med 1990;323:940-5.
6. Sause WT, Scott C, Taylor S, et al. Radiation Therapy Oncology Group (RTOG) 88-08 and Eastern Cooperative Oncology Group (ECOG) 4588: preliminary results of a phase III trial in regionally advanced, unresectable non-small-cell lung cancer. J Natl Cancer Inst 1995;87:198-205.
7. Herskovic A, Martz K, al-Sarrat M, et al. Significant advantage of chemo-radiotherapy compared to radiation alone in randomized phase III trial for patients with esophageal cancer: an Intergroup study. N Engl J Med 1992;326:1593-8.
8. Cooper J, Guo MD, Herskovic A, et al. Chemoradiotherapy of locally advanced esophageal cancer: long-term follow-up of a prospective randomized trial (RTOG 85-01). JAMA 1999;281: 1623-7.
9. Minsky B, Berkey B, Kelsen DK, et al. Preliminary results of intergroup INT 0123 randomized trial of combined modality therapy (CMT) for esophageal cancer: Standard vs. high dose radiation therapy. Proc Am Soc Clin Oncol 2000;19:239a.
10. Xie W, Chipman JG, Robertson DJ, et al. Expression of a mitogen-responsive gene encoding prostaglandin synthase is regulated by mRNA splicing. Proc Natl Acad Sci U S A 1991;88:2692-6.
11. Dubois R, Abramson SB, Crofford L, et al. Cyclooxygenase in biology and disease. FASEB J 1998;12:1063-73.
12. Koki A, Leahy K, Masferrer JL. Potential utility of COX-2 inhibition in chemoprevention and chemotherapy. Exp Opinion Investig Drugs 1999;8:1623-38.
13. Milas L. Cyclooxygenase-2 (COX-2) enzyme inhibition as potential enhancer of tumor radioresponse. Semin Radiat Oncol 2001; 11:290-9.
14. DuBois R, Smalley W. Cyclooxygenase, NSAIDs, and colorectal cancer. J Gastroenterol 1996;31:898-906.
15. Wolff H, Saukkonen K, Anttila S, et al. Expression of cyclooxygenase-2 in human lung carcinoma. Cancer Res 1998;58:4997-5001.
16. Watkins D, et al. Expression and localization of cyclo-oxygenase isoforms in non-small cell lung cancer. Eur Respir J 1999;14: 412-8.
17. Huang M, Stolina M, Sharma S, et al. Non-small cell lung cancer cyclooxygenase-2-dependent regulation of cytokine balance in lymphocytes and macrophages: up-regulation of interleukin 10 and down-regulation of interleukin 12 production. Cancer Res 1998; 58:1208-16.
18. Hida T, Yatabe Y, Achiwa H, et al. Increased expression of cyclooxygenase 2 occurs frequently in human lung cancers, specifically in adenocarcinomas. Cancer Res 1998;58:3761-4.
19. Hida T, Leyton J, Makheja AN, et al. Non-small cell lung cancer cycloxygenase activity and proliferation are inhibited by nonsteroidal antiinflammatory drugs. Anticancer Res 1998;18:775-82.
20. Achiwa H, Yatabe Y, Hida T, et al. Prognostic significance of elevated cyclooxygenase 2 expression in primary, resected lung adenocarcinomas. Clin Cancer Res 1999;5:1001-5.
21. Khuri F, Wu H, Lee JJ, et al. Cyclooxygenase-2 overexpression is a marker of poor prognosis in stage I non-small cell lung cancer. Clin Cancer Res 2001;7:861-7.
22. Kozaki K, Koshikawa K. Tatematsu Y, et al. Multi-faceted analyses of a highly metastatic human lung cancer cell line NCI-H460-LNM35 suggest mimicry of inflammatory cells in metastasis. Oncogene 2001;20:4228-34.
23. Dohadwala M, Luo J, Zhu L, et al. Non-small cell lung cancer cyclooxygenase-2-dependent invasion is mediated by CD44. J Biol Chem 2001;276:20809-12.
24. Tsubouchi Y, Mukai S, Kawahito Y, et al. Meloxicam inhibits the growth of non-small cell lung cancer. Anticancer Res 2000;20: 2867-72.
25. Rubio C. Antitumoral activity of indomethacin on experimental esophageal tumors. J Natl Cancer Inst 1984;72:705-7.
26. Funkhouser E, Sharp GB. Aspirin and reduced risk of esophageal carcinoma. Cancer 1995;76:1116-9.
27. Thun M, Namboodiri MM, Calle EE, et al. Aspirin use and risk of fatal cancer. Cancer Res 1993;53:1322-7.
28. Zimmermann KC, Sarbia M, Weber AA, et al. Cyclooxygenase-2 expression in human esophageal carcinoma. Cancer Res 1999;59: 198-204.
29. Wilson KT, Fu S, Ramanujam KS, et al. Increased expression of inducible nitric oxide synthase and cyclooxygenase-2 in Barrett's esophagus and associated adenocarcinoma. Cancer Res 1998;58: 2929-34.
30. Shirvani VN, Ouatu-Lascar R, Kaur BS, et al. Cyclooxygenase 2 expression in Barrett's esophagus and adenocarcinoma: ex vivo induction by bile salts and acid exposure. Gastroenterology 2000; 118:487-96.
31. Shamma A, Yamamoto H, Doki Y, et al. Up-regulation of cyclooxygenase-2 in squamous carcinogenesis of the esophagus. Clin Cancer Res 2000;6:1229-38.
32. Morris C, Armstrong GR, Bigley G, et al. Cyclooxygenase-2 expression in the Barrett's metaplasia-dysplasia-adenocarcinoma sequence. Am J Gastroenterol 2001;96:990-6.
33. Furuta Y, Hunter N, Barkley T Jr, et al. Increase in radioresponse of murine tumors by treatment with indomethacin. Cancer Res 1988;48:3008-13.
34. Milas L, Hanson WR. Eicosanoids and radiation. Eur J Cancer 1995;31A:1580-5.
35. Runkel S, Hunter N, Milas L. An intradermal assay for quantification and kinetics studies of tumor angiogenesis in mice. Radiat Res 1991;126:237-43.
36. Tsujii M, Kawano S, Tsuji S, et al. Cyclooxygenase regulates angiogenesis induced by colon cancer cells. Cell 1998;93:705-16.
37. Kishi K, Petersen S, Petersen C, et al. Preferential enhancement of tumor radioresponse by a cyclooxygenase-2 inhibitor. Cancer Res 2000;60:1326-31.
38. Masferrer J, Leahy KM, Koki AT, et al. Antiangiogenic and antitumor activities of cyclooxygenase-2 inhibitors. Cancer Res 2000;60:1306-11.
39. Jones M, et al. Inhibition of angiogenesis by nonsteroidal antiinflammatory drugs: insight into mechanisms and implications for cancer growth and ulcer healing. Nat Med 1999;5:1418-23.
40. Masferrer JL, Isakson PC, Seibert K. Cyclooxygenase-2 inhibitors. A new class of anti-inflammatory agents that spare the gastrointestinal tract. Gastroenterol Clin North Am 1996;25:363-72.
41. Milas L, Furuta Y, Hunter N, et al. Dependence of indomethacin-induced potentiation of murine tumor radioresponse on tumor host immunocompetence. Cancer Res 1990;50:4473-7.
42. Milas L, Kishi K, Hunter N, et al. Enhancement of tumor response to gamma-radiation by an inhibitor of cyclooxygenase-2 enzyme. J Natl Cancer Instit 1999;91:1501-4.
43. Huang M, Sharma S, Mao JT, et al. Non-small cell lung cancer-derived soluble mediators and prostaglandin E2 enhance peripheral blood lymphocyte IL-10 transcription and protein production. J Immunol 1996;157:5512-20.
44. Stolina M, Sharma S, Lin Y, et al. Specific inhibition of cyclooxygenase 2 restores antitumor reactivity by altering the balance of IL-10 and IL-12 synthesis. J Immunol 2000;164:361-70.
45. Palayoor ST, Bump EA, Calderwood SK, et al. Combined antitumor effect of radiation and ibuprofen in human prostate carcinoma cells. Clin Cancer Res 1998;4:763-71.
46. Teicher B, Palayoor S. Signal transduction inhibitors as modifiers of radiation therapy in human prostate carcinoma xenografts. Radiat Oncol Investig 1996;4:221-30.
47. Petersen C, Petersen S, Milas L, et al. Enhancement of intrinsic tumor cell radiosensitivity induced by a selective cyclooxygenase-2 inhibitor. Clin Cancer Res 2000;6:2513-20.
48. Soriano A, Helfrich B, Chan DC, et al. Synergistic effects of new chemopreventive agents and conventional cytotoxic agents against human lung cancer cell lines. Cancer Res 1999;59:6178-84.
49. Duffy C, Elliott CJ, O'Conner RA, et al. Enhancement of chemotherapeutic drug toxicity to human tumour cells in vitro by a subset of non-steroidal anti-inflammatory drugs (NSAIDs). Eur J Cancer 1998;34:1250-9.
50. Hsueh C, Chiu CF, Kelsen DP, et al. Selective inhibition of cyclooxygenase-2 enhances mitomycin-C-induced apoptosis. Cancer Chemother Pharmacol 2000;45:389-96.
51. Minna J, Gimsberg RJ, Vokes EE. In: DeVita VJ, Hellman S, Rosenberg S, eds. Cancer, principles and practice of oncology. Philadephia: Lippincott-Raven, 1997:925-983.